**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 53606

**Manuscript Type:** REVIEW

**Liver-related effects of chronic hepatitis C antiviral treatment**

Laursen TL *et al*. Effects of chronic hepatitis C antivirals

Tea L Laursen, Thomas D Sandahl, Konstantin Kazankov, Jacob George, Henning Grønbæk

**Tea L Laursen, Thomas D Sandahl, Konstantin Kazankov, Henning Grønbæk,** Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus N DK-8200, Denmark

**Jacob George,** Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital, Sydney NSW 2145, Australia

**Jacob George,** University of Sydney, Sydney NSW 2145, Australia

**Author contributions:** Laursen TL, Sandahl TD, Kazankov K, George J, and Grønbæk H designed the study; Laursen TL wrote the paper and Sandahl TD, Kazankov K, George J, and Grønbæk H critically revised it; all authors approved the final manuscript.

**Corresponding author: Tea L Laursen, MD, PhD, Doctor, Research Associate,** Department of Hepatology and Gastroenterology, Aarhus University Hospital, 99 Palle Juul-Jensens Boulevard, Entrance C, Level 1, C116, Aarhus N DK-8200, Denmark. tealaurs@rm.dk

**Received:** January 31, 2020

**Revised:** March 26, 2020

**Accepted:** May 30, 2020

**Published online:** June 14, 2020

**Abstract**

More than five years ago, the treatment of hepatitis C virus infection was revolutionized with the introduction of all-oral direct-acting antiviral (DAA) drugs. They proved highly efficient in curing patients with chronic hepatitis C (CHC), including patients with cirrhosis. The new DAA treatments were alleged to induce significant improvements in clinical outcome and prognosis, but the exact cause of the expected benefit was unclear. Further, little was known about how the underlying liver disease would be affected during and after viral clearance. In this review, we describe and discuss the liver-related effects of the new treatments in regards to both pathophysiological aspects, such as macrophage activation, and the time-dependent effects of therapy, with specific emphasis on inflammation, structural liver changes, and liver function, as these factors are all related to morbidity and mortality in CHC patients. It seems clear that antiviral therapy, especially the achievement of a sustained virologic response has several beneficial effects on liver-related parameters in CHC patients with advanced liver fibrosis or cirrhosis. There seems to be a time-dependent effect of DAA therapy with viral clearance and the resolution of liver inflammation followed by more discrete changes in structural liver lesions. These improvements lead to favorable effects on liver function, followed by an improvement in cognitive dysfunction and portal hypertension. Overall, the data provide knowledge on the several beneficial effects of DAA therapy on liver-related parameters in CHC patients suggesting short- and long-term improvements in the underlying disease with the promise of an improved long-term prognosis.

**Key words:** Chronic hepatitis C; Antiviral treatment; Inflammation; Liver fibrosis; Liver cirrhosis; Metabolic liver function; Galactose elimination capacity; Urea synthesis capacity; Portal hypertension; Hepatic encephalopathy

Laursen TL, Sandahl TD, Kazankov K, George J, Grønbæk H. Liver-related effects of chronic hepatitis C antiviral treatment. *World J Gastroenterol* 2020; 26(22): 2931-2947 URL: https://www.wjgnet.com/2219-2840/full/v26/i22/2931.htm DOI: https://dx.doi.org/10.3748/wjg.v26.i22.2931

**Core tip:** Antiviral therapy of chronic hepatitis C, especially the achievement of a sustained virologic response, has several beneficial effects on liver-related parameters in chronic hepatitis C patients. There seems to be a time-dependent effect of therapy. Initially, liver inflammation ameliorates, followed by more discrete changes in structural liver lesions. These improvements are followed by beneficial effects on liver function, cognitive disturbances, and portal hypertension. Together, this suggests short- and long-term improvements in the underlying liver disease with the promise of an improved prognosis.

**INTRODUCTION**

Hepatitis C virus (HCV) was isolated and named in 1989[1], and in 2015, more than 170 million people were infected worldwide with approximately 70 million chronically infected[2,3]. The primary mode of virus transmission in Western countries is *via* percutaneous exposure to blood, and the major infection route is unsafe drug injections[4-6]. At transmission, an acute HCV infection occurs, which is often asymptomatic[7]. In 60%-80% of patients, the infection becomes chronic[8,9], and chronic hepatitis C (CHC) is defined as positive HCV RNA for at least 6 mo. CHC holds the potential for inducing fibrosis and 10%-30% of those infected develop cirrhosis over decades, with the potential risk of complications and early death[10-12].

HCV is a hepatotropic positive single-stranded RNA virus that translates into a single polyprotein consisting of 3011 amino acids. The HCV genome is highly diverse and is separated into seven genotypes with several subtypes[13]. HCV circulates as a lipo-viro-particle consisting of the nucleocapsid surrounded by the envelope proteins E1 and E2, and several host lipoproteins[14]. HCV is cleaved by viral and host proteases into 10 proteins with diverse functions: 3 structural proteins (*i.e.*, core, E1, and E2) and 7 nonstructural (NS) proteins (*i.e.*, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B)[15,16]. The two viral proteases, NS2 and NS3/4A, are involved in the process of producing nonstructural proteins. Replication itself is catalyzed by the RNA polymerase NS5B, while NS5A and NS3 are important regulatory proteins. NS4B participates in membrane rearrangements, leading to the formation of a membranous web that supports continued HCV replication[16,17].

HCV is a major challenge for the immune system, and host factors play important roles in the potential clearance of HCV and long-term disease progression[18,19]. An initial vigorous immune response is considered crucial, and both initial and consistent innate and adaptive immune responses are important determinants of whether the infection can be cleared or becomes chronic. The innate immune responses include the activation of proinflammatory pathways[20-23], and adaptive immune factors include weak or absent HCV-specific T-cell responses[24,25]. If HCV infection is not cleared, these mechanisms lead to sustained liver inflammation with the activation of macrophages, which subsequently activate or transdifferentiate hepatic stellate cells into myofibroblast-like cells with proinflammatory, contractile, and profibrogenic properties. This may initiate a vicious cycle where inflammatory and fibrogenic cells consistently stimulate each other[26], resulting in the accumulation of excessive extracellular matrix proteins and fibrosis progression[27].

**TREATMENT OF CHRONIC HEPATITIS C**

The ultimate treatment goal of CHC is a sustained virologic response (SVR), defined as undetectable HCV RNA 12–24 wk after treatment cessation, corresponding to ‘cure’ or, in other words, HCV eradication. The treatment has evolved drastically over the last decades. For years, CHC treatment was based on subcutaneous interferon treatments that had inadequate efficacy and severe adverse effects, leaving this type of treatment intolerable for many patients, especially those with cirrhosis[28-30]. Interferon treatment acts *via* a direct immune-stimulating mechanism and has several derivative effects on innate and adaptive immunity[31]. In 2001, pegylated interferon was introduced; it has a longer half-life and a more favorable pharmacokinetic profile, and it improved the SVR rate slightly, while the majority of the adverse effects remained[32-34]. In addition to interferon treatment, ribavirin was required. Ribavirin is a nucleoside analog of guanosine that is used to potentiate the effects of antiviral treatments[35] and is still used as a potential addition to some DAA regimens.

In 2011, the first DAA treatments were introduced, and as the name infers, the DAAs are specific inhibitors of the viral proteins. Boceprevir and telaprevir were the first generation of DAAs; they inhibit the NS3/4A protease, are effective against only genotype 1, and were approved as an add-on to the established pegylated interferon and ribavirin treatment. The treatment duration was between 24 and 48 wk, and the drugs improved the SVR rates[36-39] and held promise for a new era of all-oral DAA therapy.

In 2014, sofosbuvir was marketed in Europe. Sofosbuvir is a uridine nucleotide analog that inhibits NS5B RNA polymerase by competing with natural nucleotides and by inducing viral RNA chain termination. Sofosbuvir is orally administered for 12-24 wk, is pangenotypic, and may be combined with other DAAs that are genotype-specific[40]. With the introduction of sofosbuvir, high SVR rates, in general above 90%, were reached even in difficult-to-treat patient groups, *e.g.,* patients with cirrhosis and nonresponders to previous therapy[41-44]. Several other DAAs were introduced starting in 2013, including ledipasvir (an NS5A inhibitor), daclatasvir (an NS5A inhibitor), and simeprevir (a second-generation NS3/4A inhibitor), and 3D combination (ombitasvir (an NS5A inhibitor), paritaprevir (an NS3/4A inhibitor), and ritonavir with the potential addition of dasabuvir (an NS5B inhibitor)), all of which contributed to increasing SVR rates, ultimately reaching 100%[43-47].

With the introduction of all-oral DAA therapy, a new era of CHC treatment commenced. Not only was it possible to successfully treat the ‘healthiest’ patients, but treatment was suddenly a possibility for all patients with CHC. Rapidly, the scientific discussions changed focus to special groups such as cirrhosis patients and non-responders, and to the biological effects of HCV eradication.

**ASSESSMENT OF LIVER DISEASE SEVERITY**

Assessment of liver disease severity is crucial in CHC as it is related to morbidity and mortality[48-50]. Several components affect the prognosis of chronic liver disease and the three major factors are inflammation, fibrosis, and liver function[51]. As described above, the presence of inflammation drives the process of fibrogenesis, with structural changes leading to portal hypertension. In addition, liver function may be compromised, probably due to both ongoing hepatic inflammation and structural liver changes, with the loss of functional liver mass.

***Macrophage activation***

In HCV infection, hepatocytes release viral particles and components, which may bind directly to surface or endosomal macrophage receptors or interfere indirectly with these receptors[52]. In addition, other factors may act on macrophage receptors, such as pathogen-associated molecular patterns, including lipopolysaccharide, which may enter the circulation from the gut due to increased intestinal permeability, and damage-associated molecular patterns released from damaged hepatocytes. These factors activate macrophages, causing an altered proinflammatory phenotype and amplifying hepatic inflammation[53,54]. One way to assess hepatic inflammation noninvasively is to evaluate the presence of specific macrophage activation markers in the blood. Two such markers are soluble (s)CD163 and soluble mannose receptor (sMR)[55-57] (Figure 1). sCD163 and sMR are well-established markers of liver disease severity, portal hypertension, and prognosis in several liver and infectious diseases[58-68]. Furthermore, significant associations between macrophage activation and histological inflammatory activity and fibrosis have been observed in CHC[69-71]. After antiviral therapy of chronic hepatitis B and interferon treatment of CHC, macrophage activation is diminished in parallel with the amelioration of hepatic inflammation[72,73].

***Fibrosis staging***

Fibrosis staging is important in CHC patients, as fibrosis stage is a strong predictor of complications and mortality[74,75]. Historically, liver biopsy has been the method of choice as it brings insight into the exact structure of the liver and yields information on inflammation and fibrosis as well as potential differential diagnoses. Liver histology from CHC patients covers a wide spectrum of abnormalities, from acute inflammation to lasting structural changes, often in combination[76,77]. Moreover, a liver biopsy may be used to assess fibrosis progression over time[11]. However, the biopsy represents a small portion of the liver, which may be heterogeneous. Some studies have shown sampling error in up to 30% of biopsies[78,79], with adequate biopsy length being of primary importance[80]. Liver biopsy may further be limited by inter- and intraobserver variation in histological assessment[81]; is invasive, with a small but significant risk of complications (*e.g.,* pain, bleeding, and even mortality)[82]; and is disliked by many patients, which limits its use in follow-up studies. The lack of histological verification of structural liver changes is one of the major limitations in many studies.

Due to the limitations of liver biopsy, noninvasive methods for grading and staging liver inflammation and fibrosis have become increasingly sought and used. Noninvasive methods include biomarkers and imaging techniques, many of which were developed and validated in CHC patients. The biomarkers include scores such as the aspartate aminotransferase-to-platelet ratio index (APRI) based on aspartate transaminase (AST) and platelets[83]; the fibrosis-4 (FIB-4) index based on age, AST, alanine transaminase (ALT), and platelets[84]; the enhanced liver fibrosis test[85]; and the FibroTest[86], which have all been extensively investigated in CHC patients, yielding ‘good or decent’ prediction of fibrosis and especially cirrhosis[85,87-92]. In addition, the APRI and FIB-4 predict HCV liver-related death[93].

The majority of the imaging techniques used for liver fibrosis assessment are based on the detection of the velocity of a propagating wave through liver tissue, where the velocity of the shear wave reflects tissue stiffness, with the highest velocity in the stiffest tissue. Many methods have been developed and tested, including transient elastography (TE) using the FibroScan® device (Echosens, Paris, France) and shear-wave elastographies (SWE), divided into point (p)-SWE, also known as acoustic radiation force impulse (ARFI) scans, and 2D-, and 3D-SWE. Last, magnetic resonance imaging elastography has been used in CHC patients[94]. FibroScan TE provides a measure of liver stiffness by Young’s modulus of elasticity and is expressed in kPa, whereas the ARFI scans yield the velocity of the shear wave reported in m/s.

The major quality of noninvasive fibrosis assessment inherently lies in the term noninvasive. In addition, the methods overall have practical advantages, including high applicability and good reproducibility and availability[94-97]. However, the methods also have several limitations. The performance of noninvasive methods to diagnose fibrosis or cirrhosis will depend on the prevalence of the disease stage in the cohort. This is known as spectrum bias and is especially relevant when comparing methods between cohorts. In addition, the use of noninvasive methods may be limited because most are not liver specific, and may be influenced by other factors[94,98-104].

Currently, the best validated method in CHC patients is TE using the FibroScan device. Several studies have shown good concordance between liver stiffness by FibroScan and histological stage[105,106], with good reproducibility, especially in patients with higher stages of fibrosis[107]. The ARFI method is becoming widely used and is in good agreement with liver histology in CHC patients[108,109].

***Metabolic liver function***

The liver is an extraordinary organ with numerous and highly complex functions, several of which are exclusive to the liver. In routine clinical practice, standard blood parameters such as albumin and coagulation factors are often used to assess liver function. However, a more detailed analysis can be obtained by using other methods. Some metabolic liver functions are decreased in patients with chronic hepatitis, but data on improvements after interferon therapy are conflicting[110-113]. Assessment of these functions can provide insight into CHC by linking pathophysiological events such as inflammation and fibrosis with changes in liver function and can aid understanding of how prognosis is affected after antiviral treatment[114-117].

One exclusive liver function is galactose elimination, which depends on the enzyme galactokinase, primarily located in the hepatocyte cytoplasm[118]. The test evaluates the total functional capacity of the liver to eliminate galactose from the bloodstream, reflecting functional liver cell mass; and therefore, is decreased in patients with cirrhosis[114,119].

Another exclusive, and in addition vital liver function is ureagenesis, which covers the final and irreversible transformation of amino nitrogen to urea nitrogen[120]. Ureagenesis plays a key regulatory role in whole-body nitrogen homeostasis, and disturbances in ureagenesis are associated with hepatic encephalopathy due to reduced nitrogen clearance[121]. The ureagenesis capacity also depends on functional liver mass and is compromised in cirrhosis patients[122,123].

In addition, several other methods may be used to investigate diverse liver functions. The 13C-aminopyrine breath test assesses microsomal cytochrome P450 activity of the liver[124], whereas excretory liver function may be assessed through the measurement of plasma elimination of indocyanine green (ICG)[125].

***Complications of CHC infection***

Complications of CHC infection include cirrhosis development with esophageal varices that may bleed, ascites and hepatorenal syndrome, hepatic encephalopathy (HE), and hepatocellular carcinoma (HCC). Portal hypertension is a major risk factor for an unfavorable disease course[126]. Portal hypertension may be assessed by liver vein catheterization, where wedged hepatic venous pressure is obtained in a hepatic vein and free hepatic venous pressure is measured in the right hepatic vein close to the inferior vena cava. The hepatic venous pressure gradient (HVPG) is thus determined as the difference between wedged hepatic venous pressure and free hepatic venous pressure[127]. Portal hypertension is then defined as HVPG > 5 mmHg and clinically significant portal hypertension by HVPG > 10 mmHg, which comes with a significantly increased risk of varices[128].

The presence of even minimal HE affects the quality of life, poses an increased risk of developing clinically manifest HE and is associated with a more unfavorable prognosis[129,130]. It should be noted that CHC in itself may affect cognition irrespective of HE[131]. The detection of minimal HE relies on psychometric testing, and to evaluate cognitive function in a quantitative way, several methods may be applied. The major limitation of any test to assess HE is the fact that it is only one test. Minimal HE represents complex cognitive disturbances with no single manifestation, and one test will not be able to encompass the entire spectrum of deficits in patients with HE. This is mirrored in studies showing low concordance between the continuous reaction time test and the psychometric hepatic encephalopathy score or critical-flicker frequency[132,133].

**HEPATIC EFFECTS OF ANTIVIRAL TREATMENT**

***Amelioration of inflammation***

Amelioration of inflammation is the first critical step in stopping the vicious cycle of fibrosis progression in any chronic liver disease. With viral clearance, inflammation diminishes, and this is probably required before the reversal of fibrosis and improved function can occur. Currently, it is well established that antiviral therapies, interferon- or DAA-based resolve inflammation, as indicated by biomarkers[43,44,73] and liver biopsies[33,134-137]. In addition, liver damage diminishes with reductions in ALT levels following DAA therapy, but liver-specific enhanced macrophage activation resolves rapidly with treatment[138] (Figure 2). This is supported by results from chronic hepatitis B patients, where a treatment-induced decrease in circulating sCD163 parallels diminished CD163 expression in liver biopsies[72]. In addition, it is not the effect of the treatment *per se* or the different mechanisms of action of the respective treatments but the clearance of the virus that reduces inflammation, as only patients who achieve an SVR have a decrease in sCD163[139] and achieve inflammation resolution in liver biopsies[134,136].

***Subtle changes in liver fibrosis***

To date, many studies have assessed changes in noninvasive measures after DAA therapy; improvements in several biomarker-based fibrosis panels have been shown, including APRI and FIB-4[140,141]. Several studies have also shown decreasing liver stiffness with DAA therapy[138,140,142,143]. In a 2018 review and meta-analysis of liver stiffness changes after interferon or DAA therapy, the authors showed a mean decrease of 2.4 kPa at the end of treatment, 3.1 kPa within the first 6 mo after the end of treatment, and 4.1 kPa more than 1 year after treatment. The authors speculate that the initial decrease is due partly to the resolution of inflammation and that the subsequent decrease pertains to fibrosis regression, which is supported by a larger decrease in patients with high baseline inflammation[144]. However, a consistent decrease from the end of treatment to the 1-year follow-up may represent fibrosis regression (Figure 2).

After the introduction of DAA therapy, there are only limited data from paired biopsies assessing fibrosis regression. In one study, cirrhosis resolved in seven of 14 patients[137]. In another study evaluating 10 patients with paired biopsies and liver stiffness measurements after DAA therapy, the results indicated that fibrosis regression occurs but is not as prominent as liver stiffness measurements might indicate[145]. Thus, data on changes in liver fibrosis after DAA therapy are scarce, and follow-up is still relatively short. Therefore, one can only speculate on the real effect based on the relevant literature from interferon-based studies and those using noninvasive measures. As shown by data from the interferon era, fibrosis regression or resolution takes place but is a slow process taking years[33,134-136,146], and the regression of cirrhosis is less common[136,147,148]. Additionally, it is known that fibrosis will progress without treatment[149], and progression holds an increased risk of clinical decompensation and HCC[150].

***Improved metabolic liver function***

Data on the effects of interferon treatment on galactose metabolism are conflicting. In one study where disease severity at baseline was unclear, the galactose elimination capacity (GEC) improved 3 mo after the initiation of interferon therapy[151]. This was paralleled by findings in another study with GEC improvement after 3 mo of interferon treatment, although only in responders to treatment[110], whereas others have found no effect of treatment response on the GEC[112,152].

Data on the GEC after successful DAA therapy are limited but the GEC seems to improve 12 wk post-treatment[138] (Figure 2). In these patients, GEC reflects liver disease severity and fibrosis but not inflammation[111,153].

Conversely, the amelioration of inflammation seems to improve the capacity for ureagenesis, as has also been shown in acute alcoholic hepatitis[117], which also seems to be the case in CHC patients after DAA therapy (Authors’ unpublished data). Other data concerning treatment effects on functional hepatic nitrogen clearance (FHNC) are limited, but the acceleration of the urea cycle after successful interferon therapy was demonstrated in a metabolomics study[154].

Regarding the aminopyrine breath test and ICG, no data are available after DAA therapy. However, some studies have shown improvements after interferon therapy, while others could not detect any differences[110,151].

**IMPLICATIONS FOR CLINICAL OUTCOME AND PROGNOSIS**

Treatment-naïve CHC patients have a higher risk of death compared with the background population[155,156], and the risk may be even higher in patients consuming moderate or excessive amounts of alcohol[157]. The achievement of an SVR with interferon-based treatments was associated with reduced mortality[158], in some studies, to a level comparable to the background population[159,160]; however, others find that it is still significantly higher[161]. Some have suggested that any potential outcome advantage wanes when patients are matched for liver function at baseline[162]. However, in one study in patients matched for liver function at baseline, the SVR was still associated with better survival[163]. After the development of cirrhosis, mortality is increased, and in one study of patients with CHC cirrhosis who achieved an SVR by interferon treatment, the authors showed a substantial remaining risk of HCC and clinical disease progression[164]. DAA therapy is still ‘new’ on the market, and long-term follow-up studies are limited. Based on the first studies, it seems that DAA therapy leads to an improved prognosis with decreased mortality[165-167], potentially with a significant survival benefit as soon as 18 mo post-treatment[168]. Interestingly, patients without advanced liver disease also experience reduced mortality after DAA therapy[169], while potential issues including increases in MELD scores were observed after treatment of, *e.g.,* decompensated cirrhosis patients[170]. From these studies, there seems to be a prognostic benefit in CHC patients following an SVR induced by DAA therapy, although the reasons for the benefit are not entirely clear. The available data do not provide causality; however, there are some indices suggesting that the beneficial effects of treatment on different aspects of liver disease and function may in fact lead to improved outcome.

First, low liver stiffness is a predictor of a good prognosis in patients with CHC, at least prior to therapy[171,172], but studies of noninvasive measures and associations with prognosis after DAA therapy are lacking.

Second, several studies have indicated that metabolic liver function is associated with prognosis. In one study, patients with a severely compromised GEC had a high risk of liver-related clinical outcomes[152]. Others have shown that the GEC is a strong predictor of mortality[114,173] and has prognostic value additive to the use of the Child-Pugh score[174]. Conversely, the GEC does not outperform established scores for the prediction of prognosis[175], even though the GEC was shown to be significantly higher in survivors of acute liver failure[176]. Disturbances in the urea cycle and related enzymes are associated with the severity of liver disease and potentially precede histological deterioration in chronic hepatitis[177-179]. On the basis of these results and the higher FHNC in survivors of alcoholic hepatitis[117], we speculate that improvements in metabolic liver functions may be succeeded by a better outcome in CHC patients.

Third, improvements of neurocognitive dysfunction are observed after interferon-based SVR[180]. This finding is corroborated by DAA-induced improvements in brain MR spectroscopy[181] and continuous reaction time (CRT)[138] but is not corroborated by the findings of others[182]. These discrepancies may reflect the different modalities used to assess cognitive dysfunction and the timing of the tests, *e.g.,* the CRT was not significantly improved until 1 year after treatment cessation (Figure 2). Another factor in favor of improvement in cognitive functions is self-reported mood outcomes, which are indeed improved after antiviral therapy[183].

Fourth, one of the strong predictors of adverse outcomes in cirrhosis patients is portal hypertension, and thus, its reduction is warranted. In a small study of eight patients treated with pegylated interferon, ribavirin, and boceprevir, there was a significant improvement in HVPG at 24 wk of follow-up after treatment[184]. Whereas some did not observe an improvement in HVPG at the end of DAA treatment[185], other studies indicate that DAA therapies ameliorate portal hypertension at least in long-term follow-up[186,187] (Figure 2). In addition, follow-up HVPG measurements may predict the risk of hepatic decompensation[188].

Last, the development of HCC is a risk in CHC patients, especially in those with cirrhosis[189], and the risk increases in parallel with cirrhosis severity and portal hypertension[190]. In recent years, an intense debate regarding HCC risk after successful DAA therapy has flourished. In 2016, a study showed a greatly increased risk of HCC after DAA therapy, especially HCC recurrence[191]. This was followed by other studies with similar results[192,193]. However, over recent years, more data have appeared, and the general consensus is that DAA therapy does not increase the risk of HCC[194,195], but probably decreases the risk similar to interferon-based treatments[158]. At the same time, it seems clear that the risk of HCC does not disappear after treatment and that continued and probably life-long surveillance is needed at least in cirrhosis patients or until studies have defined which patients remain at risk[196,197].

Taken together, the evidence suggests a health benefit in patients who achieve an SVR. In our opinion, causality between the improvements and improved prognosis cannot be established from the available literature. However, as reviewed above, several studies indicate such associations. The magnitude and timing of the benefit, as well as its mechanisms, remain elusive, but the data indicate that there is an association between improvements in liver inflammation, fibrosis, and metabolic function and improved outcome after an SVR.

**FUTURE ASPECTS**

Several questions to be addressed in future studies can be raised. A major question discussed in this review is whether the beneficial effects of DAA therapy on the liver in fact lead to improvements in prognosis. We speculate that liver-related improvements precede clinical benefits and improve prognosis, but confirmation is needed. Such studies require long-term follow-up and large cohorts for high enough power in terms of achieving ‘enough’ events.

Next, one could ask: how good does it get? It would be very interesting to evaluate metabolic liver function after longer follow-up to see, first, whether the improvements are sustained and second, whether further improvement occurs. Such a study would also be useful in terms of the associations between improvements in liver function and liver-related events/clinical benefit.

In addition, it is not entirely clear what happens with structural liver damage. A large study with liver biopsies after DAA therapy is warranted. In addition, such a study should include a noninvasive method to determine the degree of fibrosis. The results might enable clinicians to predict the severity of liver fibrosis after DAA therapy without the need for liver biopsies.

Another very interesting aspect is the determination of cirrhosis severity without the use of invasive methods. There is a large gap between the mere presence of cirrhosis (compensated cirrhosis) and the more severe decompensated cirrhosis, with the occurrence of clinical events. These two groups may respond differently to treatment in regard to the amelioration of liver-related effects. This needs further clarification in a study including decompensated cirrhosis patients.

Portal hypertension is a good predictor of liver-related events in cirrhosis, and a large study with liver vein catheterizations before and at long-term follow-up after DAA therapy to assess the timing and extent of improvement in portal hypertension is also in high demand.

Future studies should be designed with the usual major limitations in mind, thereby trying to minimize these limitations. They include lack of histological verification of the disease severity before treatment but especially after treatment, and in addition, the metabolic studies are often limited by sample size, as this study type is often logistically comprehensive and time-consuming.

**CONCLUSION**

From the literature, it seems clear that antiviral therapy, especially the achievement of an SVR, has several beneficial effects on liver-related parameters in CHC patients. There seems to be a time-dependent effect of DAA therapy. Initially, liver inflammation ameliorates, followed by more discrete changes in structural liver lesions. These improvements are followed by beneficial effects on metabolic liver function, cognitive disturbances, and portal hypertension (Figure 2).

In conclusion, the published data suggest short- and long-term improvements in the underlying liver disease with the promise of an improved prognosis after DAA therapy in patients with CHC and advanced liver disease.

**REFERENCES**

1 **Choo QL**, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science* 1989; **244**: 359-362 [PMID: 2523562 DOI: 10.1126/science.2523562]

2 **Polaris Observatory HCV Collaborators**. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. *Lancet Gastroenterol Hepatol* 2017; **2**: 161-176 [PMID: 28404132 DOI: 10.1016/S2468-1253(16)30181-9]

3 **Gower E**, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. *J Hepatol* 2014; **61**: S45-S57 [PMID: 25086286 DOI: 10.1016/j.jhep.2014.07.027]

4 **Dalgard O**, Egeland A, Ervik R, Vilimas K, Skaug K, Steen TW. [Risk factors for hepatitis C among injecting drug users in Oslo]. *Tidsskr Nor Laegeforen* 2009; **129**: 101-104 [PMID: 19151801 DOI: 10.4045/tidsskr.09.35002]

5 **Duberg A**, Janzon R, Bäck E, Ekdahl K, Blaxhult A. The epidemiology of hepatitis C virus infection in Sweden. *Euro Surveill* 2008; **13**: 18882 [PMID: 18761966 DOI: 10.2807/ese.13.21.18882-en]

6 **Christensen PB**, Hay G, Jepsen P, Omland LH, Just SA, Krarup HB, Weis N, Obel N, Cowan S. Hepatitis C prevalence in Denmark -an estimate based on multiple national registers. *BMC Infect Dis* 2012; **12**: 178 [PMID: 22866925 DOI: 10.1186/1471-2334-12-178]

7 **Wiese M**, Grüngreiff K, Güthoff W, Lafrenz M, Oesen U, Porst H; East German Hepatitis C Study Group. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany--a 25-year multicenter study. *J Hepatol* 2005; **43**: 590-598 [PMID: 16237783 DOI: 10.1016/j.jhep.2005.04.007]

8 **Micallef JM**, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. *J Viral Hepat* 2006; **13**: 34-41 [PMID: 16364080 DOI: 10.1111/j.1365-2893.2005.00651.x]

9 **Thomas DL**, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LE, Vlahov D. The natural history of hepatitis C virus infection: host, viral, and environmental factors. *JAMA* 2000; **284**: 450-456 [PMID: 10904508 DOI: 10.1001/jama.284.4.450]

10 **Freeman AJ**, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, Kaldor JM. Estimating progression to cirrhosis in chronic hepatitis C virus infection. *Hepatology* 2001; **34**: 809-816 [PMID: 11584380 DOI: 10.1053/jhep.2001.27831]

11 **Poynard T**, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet* 1997; **349**: 825-832 [PMID: 9121257 DOI: 10.1016/s0140-6736(96)07642-8]

12 **Ikeda K**, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. *J Hepatol* 1998; **28**: 930-938 [PMID: 9672166 DOI: 10.1016/s0168-8278(98)80339-5]

13 **Simmonds P**. The origin of hepatitis C virus. *Curr Top Microbiol Immunol* 2013; **369**: 1-15 [PMID: 23463195 DOI: 10.1007/978-3-642-27340-7\_1]

14 **André P**, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, Pol S, Bréchot C, Paranhos-Baccalà G, Lotteau V. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. *J Virol* 2002; **76**: 6919-6928 [PMID: 12072493 DOI: 10.1128/jvi.76.14.6919-6928.2002]

15 **Penin F**, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. *Hepatology* 2004; **39**: 5-19 [PMID: 14752815 DOI: 10.1002/hep.20032]

16 **Moradpour D**, Penin F. Hepatitis C virus proteins: from structure to function. *Curr Top Microbiol Immunol* 2013; **369**: 113-142 [PMID: 23463199 DOI: 10.1007/978-3-642-27340-7\_5]

17 **Lohmann V**. Hepatitis C virus RNA replication. *Curr Top Microbiol Immunol* 2013; **369**: 167-198 [PMID: 23463201 DOI: 10.1007/978-3-642-27340-7\_7]

18 **Kim AY**, Kuntzen T, Timm J, Nolan BE, Baca MA, Reyor LL, Berical AC, Feller AJ, Johnson KL, Schulze zur Wiesch J, Robbins GK, Chung RT, Walker BD, Carrington M, Allen TM, Lauer GM. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. *Gastroenterology* 2011; **140**: 686-696.e1 [PMID: 20875418 DOI: 10.1053/j.gastro.2010.09.042]

19 **Grebely J**, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, Morris MD, Hajarizadeh B, Amin J, Cox AL, Kim AY, McGovern BH, Schinkel J, George J, Shoukry NH, Lauer GM, Maher L, Lloyd AR, Hellard M, Dore GJ, Prins M; InC3 Study Group. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. *Hepatology* 2014; **59**: 109-120 [PMID: 23908124 DOI: 10.1002/hep.26639]

20 **Dolganiuc A**, Chang S, Kodys K, Mandrekar P, Bakis G, Cormier M, Szabo G. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. *J Immunol* 2006; **177**: 6758-6768 [PMID: 17082589 DOI: 10.4049/jimmunol.177.10.6758]

21 **Dolganiuc A**, Kodys K, Kopasz A, Marshall C, Do T, Romics L Jr, Mandrekar P, Zapp M, Szabo G. Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. *J Immunol* 2003; **170**: 5615-5624 [PMID: 12759441 DOI: 10.4049/jimmunol.170.11.5615]

22 **McGuinness PH**, Painter D, Davies S, McCaughan GW. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. *Gut* 2000; **46**: 260-269 [PMID: 10644323 DOI: 10.1136/gut.46.2.260]

23 **Shrivastava S**, Mukherjee A, Ray R, Ray RB. Hepatitis C virus induces interleukin-1β (IL-1β)/IL-18 in circulatory and resident liver macrophages. *J Virol* 2013; **87**: 12284-12290 [PMID: 24006444 DOI: 10.1128/JVI.01962-13]

24 **Wedemeyer H**, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, Liang TJ, Alter H, Rehermann B. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. *J Immunol* 2002; **169**: 3447-3458 [PMID: 12218168 DOI: 10.4049/jimmunol.169.6.3447]

25 **Missale G**, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, Rumi MG, Houghton M, Fiaccadori F, Ferrari C. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. *J Clin Invest* 1996; **98**: 706-714 [PMID: 8698862 DOI: 10.1172/JCI118842]

26 **Maher JJ**. Interactions between hepatic stellate cells and the immune system. *Semin Liver Dis* 2001; **21**: 417-426 [PMID: 11586469 DOI: 10.1055/s-2001-17555]

27 **Bataller R**, Brenner DA. Liver fibrosis. *J Clin Invest* 2005; **115**: 209-218 [PMID: 15690074 DOI: 10.1172/JCI24282]

28 **Poynard T**, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) *Lancet* 1998; **352**: 1426-1432 [PMID: 9807989 DOI: 10.1016/s0140-6736(98)07124-4]

29 **Shiffman ML**, Hofmann CM, Luketic VA, Sanyal AJ, Contos MJ, Mills AS. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose. *Hepatology* 1996; **24**: 21-26 [PMID: 8707264 DOI: 10.1002/hep.510240105]

30 **Idilman R**, De Maria N, Colantoni A, Dokmeci A, Van Thiel DH. Interferon treatment of cirrhotic patients with chronic hepatitis C. *J Viral Hepat* 1997; **4**: 81-91 [PMID: 9097263 DOI: 10.1111/j.1365-2893.1997.tb00209.x]

31 **Feld JJ**, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. *Nature* 2005; **436**: 967-972 [PMID: 16107837 DOI: 10.1038/nature04082]

32 **Glue P**, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. *Clin Pharmacol Ther* 2000; **68**: 556-567 [PMID: 11103758 DOI: 10.1067/mcp.2000.110973]

33 **Manns MP**, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001; **358**: 958-965 [PMID: 11583749 DOI: 10.1016/s0140-6736(01)06102-5]

34 **Fried MW**, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; **347**: 975-982 [PMID: 12324553 DOI: 10.1056/NEJMoa020047]

35 **Thomas E**, Ghany MG, Liang TJ. The application and mechanism of action of ribavirin in therapy of hepatitis C. *Antivir Chem Chemother* 2012; **23**: 1-12 [PMID: 22592135 DOI: 10.3851/IMP2125]

36 **Poordad F**, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med* 2011; **364**: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]

37 **Bacon BR**, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. *N Engl J Med* 2011; **364**: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]

38 **Jacobson IM**, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med* 2011; **364**: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1012912]

39 **Zeuzem S**, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team. Telaprevir for retreatment of HCV infection. *N Engl J Med* 2011; **364**: 2417-2428 [PMID: 21696308 DOI: 10.1056/NEJMoa1013086]

40 **Gentile I**, Maraolo AE, Buonomo AR, Zappulo E, Borgia G. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. *Expert Opin Drug Discov* 2015; **10**: 1363-1377 [PMID: 26563720 DOI: 10.1517/17460441.2015.1094051]

41 **Reddy KR**, Lim JK, Kuo A, Di Bisceglie AM, Galati JS, Morelli G, Everson GT, Kwo PY, Brown RS Jr, Sulkowski MS, Akuschevich L, Lok AS, Pockros PJ, Vainorius M, Terrault NA, Nelson DR, Fried MW, Manns MP; HCV-TARGET Study Group. All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database. *Aliment Pharmacol Ther* 2017; **45**: 115-126 [PMID: 27790729 DOI: 10.1111/apt.13823]

42 **Afdhal N**, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. *N Engl J Med* 2014; **370**: 1483-1493 [PMID: 24725238 DOI: 10.1056/NEJMoa1316366]

43 **Reddy KR**, Bourlière M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, Lawitz E, Marcellin P, Welzel TM, Hyland R, Ding X, Yang J, Knox S, Pang P, Dvory-Sobol H, Subramanian GM, Symonds W, McHutchison JG, Mangia A, Gane E, Mizokami M, Pol S, Afdhal N. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. *Hepatology* 2015; **62**: 79-86 [PMID: 25846144 DOI: 10.1002/hep.27826]

44 **Poordad F**, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, Hughes EA, Noviello S, Swenson ES. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. *Hepatology* 2016; **63**: 1493-1505 [PMID: 26754432 DOI: 10.1002/hep.28446]

45 **Aqel BA**, Pungpapong S, Leise M, Werner KT, Chervenak AE, Watt KD, Murphy JL, Ryland K, Keaveny AP, McLemore R, Vargas HE. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. *Hepatology* 2015; **62**: 1004-1012 [PMID: 26096332 DOI: 10.1002/hep.27937]

46 **Poordad F**, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. *N Engl J Med* 2014; **370**: 1973-1982 [PMID: 24725237 DOI: 10.1056/NEJMoa1402869]

47 **Ferenci P**, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR; PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. *N Engl J Med* 2014; **370**: 1983-1992 [PMID: 24795200 DOI: 10.1056/NEJMoa1402338]

48 **D'Amico G**, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. *J Hepatol* 2006; **44**: 217-231 [PMID: 16298014 DOI: 10.1016/j.jhep.2005.10.013]

49 **Niederau C**, Lange S, Heintges T, Erhardt A, Buschkamp M, Hürter D, Nawrocki M, Kruska L, Hensel F, Petry W, Häussinger D. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. *Hepatology* 1998; **28**: 1687-1695 [PMID: 9828236 DOI: 10.1002/hep.510280632]

50 **Bruno S**, Zuin M, Crosignani A, Rossi S, Zadra F, Roffi L, Borzio M, Redaelli A, Chiesa A, Silini EM, Almasio PL, Maisonneuve P. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. *Am J Gastroenterol* 2009; **104**: 1147-1158 [PMID: 19352340 DOI: 10.1038/ajg.2009.31]

51 **Marcellin P**, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. *Hepatology* 2002; **36**: S47-S56 [PMID: 12407576 DOI: 10.1053/jhep.2002.36993]

52 **Heydtmann M**. Macrophages in hepatitis B and hepatitis C virus infections. *J Virol* 2009; **83**: 2796-2802 [PMID: 18842723 DOI: 10.1128/JVI.00996-08]

53 **Schnabl B**, Brenner DA. Interactions between the intestinal microbiome and liver diseases. *Gastroenterology* 2014; **146**: 1513-1524 [PMID: 24440671 DOI: 10.1053/j.gastro.2014.01.020]

54 **Kubes P**, Mehal WZ. Sterile inflammation in the liver. *Gastroenterology* 2012; **143**: 1158-1172 [PMID: 22982943 DOI: 10.1053/j.gastro.2012.09.008]

55 **Møller HJ**, Hald K, Moestrup SK. Characterization of an enzyme-linked immunosorbent assay for soluble CD163. *Scand J Clin Lab Invest* 2002; **62**: 293-299 [PMID: 12476928 DOI: 10.1080/003655102760145852]

56 **Rødgaard-Hansen S**, Rafique A, Christensen PA, Maniecki MB, Sandahl TD, Nexø E, Møller HJ. A soluble form of the macrophage-related mannose receptor (MR/CD206) is present in human serum and elevated in critical illness. *Clin Chem Lab Med* 2014; **52**: 453-461 [PMID: 24114918 DOI: 10.1515/cclm-2013-0451]

57 **Martinez-Pomares L**. The mannose receptor. *J Leukoc Biol* 2012; **92**: 1177-1186 [PMID: 22966131 DOI: 10.1189/jlb.0512231]

58 **Rødgaard-Hansen S**, Rafique A, Weis N, Wejse C, Nielsen H, Pedersen SS, Møller HJ, Kronborg G. Increased concentrations of the soluble mannose receptor in serum from patients with pneumococcal bacteraemia, and prediction of survival. *Infect Dis (Lond)* 2015; **47**: 203-208 [PMID: 25650730 DOI: 10.3109/00365548.2014.984321]

59 **Holland-Fischer P**, Grønbæk H, Sandahl TD, Moestrup SK, Riggio O, Ridola L, Aagaard NK, Møller HJ, Vilstrup H. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. *Gut* 2011; **60**: 1389-1393 [PMID: 21572121 DOI: 10.1136/gut.2010.234542]

60 **Grønbæk H**, Rødgaard-Hansen S, Aagaard NK, Arroyo V, Moestrup SK, Garcia E, Solà E, Domenicali M, Piano S, Vilstrup H, Møller HJ; CANONIC study investigators of the EASL-CLIF Consortium. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). *J Hepatol* 2016; **64**: 813-822 [PMID: 26639396 DOI: 10.1016/j.jhep.2015.11.021]

61 **Grønbaek H**, Sandahl TD, Mortensen C, Vilstrup H, Møller HJ, Møller S. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. *Aliment Pharmacol Ther* 2012; **36**: 173-180 [PMID: 22591184 DOI: 10.1111/j.1365-2036.2012.05134.x]

62 **Laursen TL**, Rødgaard-Hansen S, Møller HJ, Mortensen C, Karlsen S, Nielsen DT, Frevert S, Clemmesen JO, Møller S, Jensen JS, Bendtsen F, Grønbaek H. The soluble mannose receptor is released from the liver in cirrhotic patients, but is not associated with bacterial translocation. *Liver Int* 2017; **37**: 569-575 [PMID: 27706896 DOI: 10.1111/liv.13262]

63 **Sandahl TD**, Støy SH, Laursen TL, Rødgaard-Hansen S, Møller HJ, Møller S, Vilstrup H, Grønbæk H. The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients. *PLoS One* 2017; **12**: e0189345 [PMID: 29236785 DOI: 10.1371/journal.pone.0189345]

64 **Rode A**, Nicoll A, Møller HJ, Lim L, Angus PW, Kronborg I, Arachchi N, Gorelik A, Liew D, Kazankov K, Vilstrup H, Grønbæk H. Hepatic macrophage activation predicts clinical decompensation in chronic liver disease. *Gut* 2013; **62**: 1231-1232 [PMID: 23442440 DOI: 10.1136/gutjnl-2012-304135]

65 **Waidmann O**, Köberle V, Bettinger D, Trojan J, Zeuzem S, Schultheiß M, Kronenberger B, Piiper A. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. *J Hepatol* 2013; **59**: 769-779 [PMID: 23792028 DOI: 10.1016/j.jhep.2013.06.008]

66 **Waidmann O**, Brunner F, Herrmann E, Zeuzem S, Piiper A, Kronenberger B. Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis. *J Hepatol* 2013; **58**: 956-961 [PMID: 23333526 DOI: 10.1016/j.jhep.2013.01.005]

67 **Kazankov K**, Rode A, Simonsen K, Villadsen GE, Nicoll A, Møller HJ, Lim L, Angus P, Kronborg I, Arachchi N, Gorelik A, Liew D, Vilstrup H, Frystyk J, Grønbæk H. Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma. *Scand J Clin Lab Invest* 2016; **76**: 64-73 [PMID: 26549495 DOI: 10.3109/00365513.2015.1099722]

68 **Kazankov K**, Tordjman J, Møller HJ, Vilstrup H, Poitou C, Bedossa P, Bouillot JL, Clement K, Grønbaek H. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery. *J Gastroenterol Hepatol* 2015; **30**: 1293-1300 [PMID: 25772748 DOI: 10.1111/jgh.12943]

69 **Kazankov K**, Barrera F, Møller HJ, Bibby BM, Vilstrup H, George J, Grønbaek H. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. *Hepatology* 2014; **60**: 521-530 [PMID: 24623375 DOI: 10.1002/hep.27129]

70 **Dultz G**, Gerber L, Farnik H, Berger A, Vermehren J, Pleli T, Zeuzem S, Piiper A, Kronenberger B, Waidmann O. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus. *J Viral Hepat* 2015; **22**: 427-432 [PMID: 25181653 DOI: 10.1111/jvh.12309]

71 **Andersen ES**, Rødgaard-Hansen S, Moessner B, Christensen PB, Møller HJ, Weis N. Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study. *Eur J Clin Microbiol Infect Dis* 2014; **33**: 117-122 [PMID: 24424890 DOI: 10.1007/s10096-013-1936-3]

72 **Laursen TL**, Wong GL, Kazankov K, Sandahl T, Møller HJ, Hamilton-Dutoit S, George J, Chan HL, Grønbaek H. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. *J Gastroenterol Hepatol* 2018; **33**: 484-491 [PMID: 28618015 DOI: 10.1111/jgh.13849]

73 **Dultz G**, Gerber L, Zeuzem S, Sarrazin C, Waidmann O. The macrophage activation marker CD163 is associated with IL28B genotype and hepatic inflammation in chronic hepatitis C virus infected patients. *J Viral Hepat* 2016; **23**: 267-273 [PMID: 26554542 DOI: 10.1111/jvh.12488]

74 **Xu F**, Moorman AC, Tong X, Gordon SC, Rupp LB, Lu M, Teshale EH, Spradling PR, Boscarino JA, Trinacty CM, Schmidt MA, Holmberg SD; Chronic Hepatitis Cohort Study (CHeCS) Investigators, Holmberg SD, Teshale EH, Spradling PR, Moorman AC, Xing J, Tong X, Xu F, Gordon SC, Nerenz DR, Lu M, Lamerato L, Wang Y, Rupp LB, Akkerman N, Oja-Tebbe N, Zhang T, Li J, Sitarik A, Larkin D, Boscarino JA, Daar ZS, Curry PJ, Smith RE, Vijayadeva V, Parker JV, Schmidt MA, Donald JL, Keast EM. All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus. *Clin Infect Dis* 2016; **62**: 289-297 [PMID: 26417034 DOI: 10.1093/cid/civ860]

75 **Bruden DJT**, McMahon BJ, Townshend-Bulson L, Gounder P, Gove J, Plotnik J, Homan C, Hewitt A, Barbour Y, Spradling PR, Simons BC, McArdle S, Bruce M. Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort. *Hepatology* 2017; **66**: 37-45 [PMID: 28195349 DOI: 10.1002/hep.29115]

76 **Scheuer PJ**, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. *Hepatology* 1992; **15**: 567-571 [PMID: 1551631 DOI: 10.1002/hep.1840150402]

77 **Dienes HP**, Popper H, Arnold W, Lobeck H. Histologic observations in human hepatitis non-A, non-B. *Hepatology* 1982; **2**: 562-571 [PMID: 6811393 DOI: 10.1002/hep.1840020509]

78 **Regev A**, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol* 2002; **97**: 2614-2618 [PMID: 12385448 DOI: 10.1111/j.1572-0241.2002.06038.x]

79 **Maharaj B**, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, Pudifin DJ. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. *Lancet* 1986; **1**: 523-525 [PMID: 2869260 DOI: 10.1016/s0140-6736(86)90883-4]

80 **Bedossa P**, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. *Hepatology* 2003; **38**: 1449-1457 [PMID: 14647056 DOI: 10.1016/j.hep.2003.09.022]

81 **Cholongitas E**, Senzolo M, Standish R, Marelli L, Quaglia A, Patch D, Dhillon AP, Burroughs AK. A systematic review of the quality of liver biopsy specimens. *Am J Clin Pathol* 2006; **125**: 710-721 [PMID: 16707372 DOI: 10.1309/W3XC-NT4H-KFBN-2G0B]

82 **Bravo AA**, Sheth SG, Chopra S. Liver biopsy. *N Engl J Med* 2001; **344**: 495-500 [PMID: 11172192 DOI: 10.1056/NEJM200102153440706]

83 **Wai CT**, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003; **38**: 518-526 [PMID: 12883497 DOI: 10.1053/jhep.2003.50346]

84 **Sterling RK**, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology* 2006; **43**: 1317-1325 [PMID: 16729309 DOI: 10.1002/hep.21178]

85 **Lichtinghagen R**, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. *J Hepatol* 2013; **59**: 236-242 [PMID: 23523583 DOI: 10.1016/j.jhep.2013.03.016]

86 **Imbert-Bismut F**, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T; MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. *Lancet* 2001; **357**: 1069-1075 [PMID: 11297957 DOI: 10.1016/S0140-6736(00)04258-6]

87 **Shaheen AA**, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. *Hepatology* 2007; **46**: 912-921 [PMID: 17705266 DOI: 10.1002/hep.21835]

88 **Poynard T**, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, de Ledinghen V. Meta-analyses of FibroTest diagnostic value in chronic liver disease. *BMC Gastroenterol* 2007; **7**: 40 [PMID: 17937811 DOI: 10.1186/1471-230X-7-40]

89 **Ragazzo TG**, Paranagua-Vezozzo D, Lima FR, de Campos Mazo DF, Pessoa MG, Oliveira CP, Alves VAF, Carrilho FJ. Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C. *Clinics (Sao Paulo)* 2017; **72**: 516-525 [PMID: 29069254 DOI: 10.6061/clinics/2017(09)01]

90 **Yen YH**, Kuo FY, Kee KM, Chang KC, Tsai MC, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH. APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level. *PLoS One* 2018; **13**: e0199760 [PMID: 29953518 DOI: 10.1371/journal.pone.0199760]

91 **Petersen JR**, Stevenson HL, Kasturi KS, Naniwadekar A, Parkes J, Cross R, Rosenberg WM, Xiao SY, Snyder N. Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C. *J Clin Gastroenterol* 2014; **48**: 370-376 [PMID: 24045284 DOI: 10.1097/MCG.0b013e3182a87e78]

92 **Martinez SM**, Fernández-Varo G, González P, Sampson E, Bruguera M, Navasa M, Jiménez W, Sánchez-Tapias JM, Forns X. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. *Aliment Pharmacol Ther* 2011; **33**: 138-148 [PMID: 21083589 DOI: 10.1111/j.1365-2036.2010.04500.x]

93 **Nunes D**, Fleming C, Offner G, Craven D, Fix O, Heeren T, Koziel MJ, Graham C, Tumilty S, Skolnik P, Stuver S, Horsburgh CR Jr, Cotton D. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. *Am J Gastroenterol* 2010; **105**: 1346-1353 [PMID: 20179698 DOI: 10.1038/ajg.2009.746]

94 **European Association for Study of Liver**; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. *J Hepatol* 2015; **63**: 237-264 [PMID: 25911335 DOI: 10.1016/j.jhep.2015.04.006]

95 **Castera L**, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. *J Hepatol* 2008; **48**: 835-847 [PMID: 18334275 DOI: 10.1016/j.jhep.2008.02.008]

96 **Bota S**, Sporea I, Sirli R, Popescu A, Danila M, Costachescu D. Intra- and interoperator reproducibility of acoustic radiation force impulse (ARFI) elastography--preliminary results. *Ultrasound Med Biol* 2012; **38**: 1103-1108 [PMID: 22579536 DOI: 10.1016/j.ultrasmedbio.2012.02.032]

97 **Boursier J**, Isselin G, Fouchard-Hubert I, Oberti F, Dib N, Lebigot J, Bertrais S, Gallois Y, Calès P, Aubé C. Acoustic radiation force impulse: a new ultrasonographic technology for the widespread noninvasive diagnosis of liver fibrosis. *Eur J Gastroenterol Hepatol* 2010; **22**: 1074-1084 [PMID: 20440210 DOI: 10.1097/MEG.0b013e328339e0a1]

98 **Castéra L**, Foucher J, Bernard PH, Carvalho F, Allaix D, Merrouche W, Couzigou P, de Lédinghen V. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. *Hepatology* 2010; **51**: 828-835 [PMID: 20063276 DOI: 10.1002/hep.23425]

99 **Coco B**, Oliveri F, Maina AM, Ciccorossi P, Sacco R, Colombatto P, Bonino F, Brunetto MR. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. *J Viral Hepat* 2007; **14**: 360-369 [PMID: 17439526 DOI: 10.1111/j.1365-2893.2006.00811.x]

100 **Arena U**, Vizzutti F, Corti G, Ambu S, Stasi C, Bresci S, Moscarella S, Boddi V, Petrarca A, Laffi G, Marra F, Pinzani M. Acute viral hepatitis increases liver stiffness values measured by transient elastography. *Hepatology* 2008; **47**: 380-384 [PMID: 18095306 DOI: 10.1002/hep.22007]

101 **Millonig G**, Reimann FM, Friedrich S, Fonouni H, Mehrabi A, Büchler MW, Seitz HK, Mueller S. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. *Hepatology* 2008; **48**: 1718-1723 [PMID: 18836992 DOI: 10.1002/hep.22577]

102 **Kjærgaard M**, Thiele M, Jansen C, Stæhr Madsen B, Görtzen J, Strassburg C, Trebicka J, Krag A. High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal. *PLoS One* 2017; **12**: e0173992 [PMID: 28376114 DOI: 10.1371/journal.pone.0173992]

103 **Popescu A**, Bota S, Sporea I, Sirli R, Danila M, Racean S, Suseanu D, Gradinaru O, Ivascu Siegfried C. The influence of food intake on liver stiffness values assessed by acoustic radiation force impulse elastography-preliminary results. *Ultrasound Med Biol* 2013; **39**: 579-584 [PMID: 23415282 DOI: 10.1016/j.ultrasmedbio.2012.11.013]

104 **Bota S**, Sporea I, Peck-Radosavljevic M, Sirli R, Tanaka H, Iijima H, Saito H, Ebinuma H, Lupsor M, Badea R, Fierbinteanu-Braticevici C, Petrisor A, Friedrich-Rust M, Sarrazin C, Takahashi H, Ono N, Piscaglia F, Marinelli S, D'Onofrio M, Gallotti A, Salzl P, Popescu A, Danila M. The influence of aminotransferase levels on liver stiffness assessed by Acoustic Radiation Force Impulse Elastography: a retrospective multicentre study. *Dig Liver Dis* 2013; **45**: 762-768 [PMID: 23510533 DOI: 10.1016/j.dld.2013.02.008]

105 **Castéra L**, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology* 2005; **128**: 343-350 [PMID: 15685546 DOI: 10.1053/j.gastro.2004.11.018]

106 **Ziol M**, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Lédinghen V, Marcellin P, Dhumeaux D, Trinchet JC, Beaugrand M. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. *Hepatology* 2005; **41**: 48-54 [PMID: 15690481 DOI: 10.1002/hep.20506]

107 **Fraquelli M**, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, Colombo M. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. *Gut* 2007; **56**: 968-973 [PMID: 17255218 DOI: 10.1136/gut.2006.111302]

108 **Fierbinteanu-Braticevici C**, Andronescu D, Usvat R, Cretoiu D, Baicus C, Marinoschi G. Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis. *World J Gastroenterol* 2009; **15**: 5525-5532 [PMID: 19938190 DOI: 10.3748/wjg.15.5525]

109 **Friedrich-Rust M**, Wunder K, Kriener S, Sotoudeh F, Richter S, Bojunga J, Herrmann E, Poynard T, Dietrich CF, Vermehren J, Zeuzem S, Sarrazin C. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. *Radiology* 2009; **252**: 595-604 [PMID: 19703889 DOI: 10.1148/radiol.2523081928]

110 **Ocker M**, Ganslmayer M, Zopf S, Gahr S, Janson C, Hahn EG, Herold C. Improvement of quantitative testing of liver function in patients with chronic hepatitis C after installment of antiviral therapy. *World J Gastroenterol* 2005; **11**: 5521-5524 [PMID: 16222747 DOI: 10.3748/wjg.v11.i35.5521]

111 **Herold C**, Heinz R, Radespiel-Tröger M, Schneider HT, Schuppan D, Hahn EG. Quantitative testing of liver function in patients with cirrhosis due to chronic hepatitis C to assess disease severity. *Liver* 2001; **21**: 26-30 [PMID: 11169069 DOI: 10.1034/j.1600-0676.2001.210104.x]

112 **Reichen J**, Solioz M, Bühler H, Gonvers JJ, Knoblauch M, Lavanchy D, Malé PJ, Meyer B, Schmid M, Bianchi L. Low-dose interferon in chronic hepatitis non-A/non-B: effects on quantitative liver function and structure in a randomized, controlled multicenter trial. *Clin Investig* 1993; **71**: 888-893 [PMID: 7508773 DOI: 10.1007/BF00185598]

113 **Bianchi G**, Marchesini G, Vilstrup H, Fabbri A, De Mitri MS, Zoli M, Pisi E. Hepatic amino-nitrogen clearance to urea-nitrogen in control subjects and in patients with cirrhosis: a simplified method. *Hepatology* 1991; **13**: 460-466 [PMID: 1999317]

114 **Jepsen P**, Vilstrup H, Ott P, Keiding S, Andersen PK, Tygstrup N. The galactose elimination capacity and mortality in 781 Danish patients with newly-diagnosed liver cirrhosis: a cohort study. *BMC Gastroenterol* 2009; **9**: 50 [PMID: 19566919 DOI: 10.1186/1471-230X-9-50]

115 **Merkel C**, Marchesini G, Fabbri A, Bianco S, Bianchi G, Enzo E, Sacerdoti D, Zoli M, Gatta A. The course of galactose elimination capacity in patients with alcoholic cirrhosis: possible use as a surrogate marker for death. *Hepatology* 1996; **24**: 820-823 [PMID: 8855183 DOI: 10.1053/jhep.1996.v24.pm0008855183]

116 **Schmidt LE**, Ott P, Tygstrup N. Galactose elimination capacity as a prognostic marker in patients with severe acetaminophen-induced hepatotoxicity: 10 years' experience. *Clin Gastroenterol Hepatol* 2004; **2**: 418-424 [PMID: 15118981 DOI: 10.1016/s1542-3565(04)00128-4]

117 **Glavind E**, Aagaard NK, Gronbaek H, Orntoft NW, Vilstrup H, Thomsen KL. Time course of compromised urea synthesis in patients with alcoholic hepatitis. *Scand J Gastroenterol* 2018; **53**: 592-597 [PMID: 29113530 DOI: 10.1080/00365521.2017.1399163]

118 **Frey PA**. The Leloir pathway: a mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose. *FASEB J* 1996; **10**: 461-470 [PMID: 8647345]

119 **Tygstrup N**. The galactose elimination capacity in control subjects and in patients with cirrhosis of the liver. *Acta Med Scand* 1964; **175**: 281-289 [PMID: 14136243 DOI: 10.1111/j.0954-6820.1964.tb00576.x]

120 **Vilstrup H**. Synthesis of urea after stimulation with amino acids: relation to liver function. *Gut* 1980; **21**: 990-995 [PMID: 7450564 DOI: 10.1136/gut.21.11.990]

121 **Meijer AJ**, Lamers WH, Chamuleau RA. Nitrogen metabolism and ornithine cycle function. *Physiol Rev* 1990; **70**: 701-748 [PMID: 2194222 DOI: 10.1152/physrev.1990.70.3.701]

122 **Rafoth RJ**, Onstad GR. Urea synthesis after oral protein ingestion in man. *J Clin Invest* 1975; **56**: 1170-1174 [PMID: 1184743 DOI: 10.1172/JCI108193]

123 **Sandahl TD**, Aagaard NK, Thomsen KL, Grøfte T, Greisen J, Christiansen JS, Vilstrup H. Effects of insulin-like growth factor-I administration on in vivo regulation of urea synthesis in normal subjects and patients with cirrhosis. *Liver Int* 2011; **31**: 132-137 [PMID: 21040412 DOI: 10.1111/j.1478-3231.2010.02362.x]

124 **Armuzzi A**, Candelli M, Zocco MA, Andreoli A, De Lorenzo A, Nista EC, Miele L, Cremonini F, Cazzato IA, Grieco A, Gasbarrini G, Gasbarrini A. Review article: breath testing for human liver function assessment. *Aliment Pharmacol Ther* 2002; **16**: 1977-1996 [PMID: 12452932 DOI: 10.1046/j.1365-2036.2002.01374.x]

125 **Nielsen NC**. Spectrophotometric determination of indocyanine green in plasma especially with a view to an improved correction for blank density. *Scand J Clin Lab Invest* 1963; **15**: 613-621 [PMID: 14077016 DOI: 10.3109/00365516309051344]

126 **D'Amico G**, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. *Gastroenterology* 2006; **131**: 1611-1624 [PMID: 17101332 DOI: 10.1053/j.gastro.2006.09.013]

127 **Keiding S**, Vilstrup H. Intrahepatic heterogeneity of hepatic venous pressure gradient in human cirrhosis. *Scand J Gastroenterol* 2002; **37**: 960-964 [PMID: 12229973 DOI: 10.1080/003655202760230946]

128 **de Franchis R**; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. *J Hepatol* 2015; **63**: 743-752 [PMID: 26047908 DOI: 10.1016/j.jhep.2015.05.022]

129 **Das A**, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. *J Gastroenterol Hepatol* 2001; **16**: 531-535 [PMID: 11350549 DOI: 10.1046/j.1440-1746.2001.02487.x]

130 **Amodio P**, Del Piccolo F, Marchetti P, Angeli P, Iemmolo R, Caregaro L, Merkel C, Gerunda G, Gatta A. Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. *Hepatology* 1999; **29**: 1662-1667 [PMID: 10347105 DOI: 10.1002/hep.510290619]

131 **Campagna F**, Montagnese S, Schiff S, Ruzzoli M, Biancardi A, Iannizzi P, Pujatti PL, Angeli P, Gatta A, Merkel C, Leandro G, Mapelli D, Amodio P. Confounders in the detection of minimal hepatic encephalopathy: a neuropsychological and quantified EEG study. *Liver Int* 2015; **35**: 1524-1532 [PMID: 25040245 DOI: 10.1111/liv.12635]

132 **Lauridsen MM**, Jepsen P, Vilstrup H. Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: a comparative study of 154 patients with liver disease. *Metab Brain Dis* 2011; **26**: 135-139 [PMID: 21484318 DOI: 10.1007/s11011-011-9242-1]

133 **Lauridsen MM**, Schaffalitzky de Muckadell OB, Vilstrup H. Minimal hepatic encephalopathy characterized by parallel use of the continuous reaction time and portosystemic encephalopathy tests. *Metab Brain Dis* 2015; **30**: 1187-1192 [PMID: 26016624 DOI: 10.1007/s11011-015-9688-7]

134 **Shiratori Y**, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. *Ann Intern Med* 2000; **132**: 517-524 [PMID: 10744587 DOI: 10.7326/0003-4819-132-7-200004040-00002]

135 **Toccaceli F**, Laghi V, Capurso L, Koch M, Sereno S, Scuderi M; Italian Hepanet Group. Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon. *J Viral Hepat* 2003; **10**: 126-133 [PMID: 12614469 DOI: 10.1046/j.1365-2893.2003.00403.x]

136 **Shiffman ML**, Sterling RK, Contos M, Hubbard S, Long A, Luketic VA, Stravitz RT, Fuchs M, Sanyal AJ. Long term changes in liver histology following treatment of chronic hepatitis C virus. *Ann Hepatol* 2014; **13**: 340-349 [PMID: 24927604]

137 **Schwabl P**, Mandorfer M, Steiner S, Scheiner B, Chromy D, Herac M, Bucsics T, Hayden H, Grabmeier-Pfistershammer K, Ferlitsch A, Oberhuber G, Trauner M, Peck-Radosavljevic M, Reiberger T. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. *Aliment Pharmacol Ther* 2017; **45**: 139-149 [PMID: 27910154 DOI: 10.1111/apt.13844]

138 **Laursen TL**, Siggaard CB, Kazankov K, Sandahl TD, Møller HJ, Tarp B, Kristensen LH, Laursen AL, Leutscher P, Grønbaek H. Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C. *J Viral Hepat* 2020; **27**: 28-35 [PMID: 31502741 DOI: 10.1111/jvh.13204]

139 **Lund Laursen T**, Brøckner Siggard C, Kazankov K, Damgaard Sandahl T, Møller HJ, Ong A, Douglas MW, George J, Tarp B, Hagelskjaer Kristensen L, Lund Laursen A, Hiramatsu A, Nakahara T, Chayama K, Grønbaek H. Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology. *Scand J Gastroenterol* 2018; **53**: 986-993 [PMID: 29987961 DOI: 10.1080/00365521.2018.1481996]

140 **Knop V**, Hoppe D, Welzel T, Vermehren J, Herrmann E, Vermehren A, Friedrich-Rust M, Sarrazin C, Zeuzem S, Welker MW. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. *J Viral Hepat* 2016; **23**: 994-1002 [PMID: 27500382 DOI: 10.1111/jvh.12578]

141 **Elsharkawy A**, Alem SA, Fouad R, El Raziky M, El Akel W, Abdo M, Tantawi O, AbdAllah M, Bourliere M, Esmat G. Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. *J Gastroenterol Hepatol* 2017; **32**: 1624-1630 [PMID: 28177543 DOI: 10.1111/jgh.13758]

142 **Kobayashi N**, Iijima H, Tada T, Kumada T, Yoshida M, Aoki T, Nishimura T, Nakano C, Takata R, Yoh K, Ishii A, Takashima T, Sakai Y, Aizawa N, Nishikawa H, Ikeda N, Iwata Y, Enomoto H, Hirota S, Fujimoto J, Nishiguchi S. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. *Eur J Gastroenterol Hepatol* 2018; **30**: 546-551 [PMID: 29494353 DOI: 10.1097/MEG.0000000000001106]

143 **Lens S**, Alvarado-Tapias E, Mariño Z, Londoño MC, LLop E, Martinez J, Fortea JI, Ibañez L, Ariza X, Baiges A, Gallego A, Bañares R, Puente A, Albillos A, Calleja JL, Torras X, Hernández-Gea V, Bosch J, Villanueva C, Forns X, García-Pagán JC. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. *Gastroenterology* 2017; **153**: 1273-1283.e1 [PMID: 28734831 DOI: 10.1053/j.gastro.2017.07.016]

144 **Singh S**, Facciorusso A, Loomba R, Falck-Ytter YT. Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol* 2018; **16**: 27-38.e4 [PMID: 28479504 DOI: 10.1016/j.cgh.2017.04.038]

145 **Pockros P,** Crissien-Martinez AM, Frenette C, Skillin C, Bao F, Du E, Pan JJ, Waalen J. Degree of liver fibrosis regression predicted by transient elastography after cure of chronic hepatitis C with direct acting antivirals is overestimated but confirmed by liver biopsy. *J Hepatol* 2017; **66**: S108 [DOI: 10.1016/S0168-8278(17)30475-0]

146 **Poynard T**, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. *Gastroenterology* 2002; **122**: 1303-1313 [PMID: 11984517 DOI: 10.1053/gast.2002.33023]

147 **D'Ambrosio R**, Aghemo A, Rumi MG, Ronchi G, Donato MF, Paradis V, Colombo M, Bedossa P. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. *Hepatology* 2012; **56**: 532-543 [PMID: 22271347 DOI: 10.1002/hep.25606]

148 **Manne V**, Akhtar E, Saab S. Cirrhosis regression in patients with viral hepatitis B and C: a systematic review. *J Clin Gastroenterol* 2014; **48**: e76-e84 [PMID: 24921210 DOI: 10.1097/MCG.0000000000000162]

149 **Ghany MG**, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, Herion D, Park Y, Liang TJ, Hoofnagle JH. Progression of fibrosis in chronic hepatitis C. *Gastroenterology* 2003; **124**: 97-104 [PMID: 12512034 DOI: 10.1053/gast.2003.50018]

150 **Hoefs JC**, Shiffman ML, Goodman ZD, Kleiner DE, Dienstag JL, Stoddard AM; HALT-C Trial Group. Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial. *Gastroenterology* 2011; **141**: 900-908.e1-2 [PMID: 21699796 DOI: 10.1053/j.gastro.2011.06.007]

151 **Stintzing S**, Schmitt C, Ocker M, Ganslmayer M, Zopf S, Gahr S, Hahn EG, Herold C. Liver function under interferon/ribavirin therapy of chronic hepatitis C. *Hepatogastroenterology* 2009; **56**: 462-465 [PMID: 19579621]

152 **Everson GT**, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, Lauriski S, Curto TM, Stoddard A, Wright EC; HALT-C Trial Group. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. *Hepatology* 2012; **55**: 1019-1029 [PMID: 22030902 DOI: 10.1002/hep.24752]

153 **Herold C**, Heinz R, Niedobitek G, Schneider T, Hahn EG, Schuppan D. Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C. *Liver* 2001; **21**: 260-265 [PMID: 11454189 DOI: 10.1034/j.1600-0676.2001.021004260.x]

154 **Chang ML**, Cheng ML, Chang SW, Tang HY, Chiu CT, Yeh CT, Shiao MS. Recovery of pan-genotypic and genotype-specific amino acid alterations in chronic hepatitis C after viral clearance: transition at the crossroad of metabolism and immunity. *Amino Acids* 2017; **49**: 291-302 [PMID: 27830380 DOI: 10.1007/s00726-016-2360-7]

155 **El-Kamary SS**, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. *Clin Infect Dis* 2011; **53**: 150-157 [PMID: 21665867 DOI: 10.1093/cid/cir306]

156 **Omland LH**, Krarup H, Jepsen P, Georgsen J, Harritshøj LH, Riisom K, Jacobsen SE, Schouenborg P, Christensen PB, Sørensen HT, Obel N; DANVIR Cohort Study. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. *J Hepatol* 2010; **53**: 36-42 [PMID: 20400197 DOI: 10.1016/j.jhep.2010.01.033]

157 **Younossi ZM**, Zheng L, Stepanova M, Venkatesan C, Mir HM. Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C. *Aliment Pharmacol Ther* 2013; **37**: 703-709 [PMID: 23432436 DOI: 10.1111/apt.12265]

158 **van der Meer AJ**, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. *JAMA* 2012; **308**: 2584-2593 [PMID: 23268517 DOI: 10.1001/jama.2012.144878]

159 **Bruno S**, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, Aghemo A, Cabibbo G, Viganò M, Boccaccio V, Craxí A, Colombo M, Maisonneuve P. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. *J Hepatol* 2016; **64**: 1217-1223 [PMID: 27059129 DOI: 10.1016/j.jhep.2016.01.034]

160 **Bruno S**, Maisonneuve P. Reply to: "Methodological considerations when calculating person-time at risk for patients with chronic hepatitis C undergoing antiviral treatment". *J Hepatol* 2017; **67**: 428-429 [PMID: 28435040 DOI: 10.1016/j.jhep.2017.04.005]

161 **Innes H**, McDonald S, Hayes P, Dillon JF, Allen S, Goldberg D, Mills PR, Barclay ST, Wilks D, Valerio H, Fox R, Bhattacharyya D, Kennedy N, Morris J, Fraser A, Stanley A, Bramley P, Hutchinson SJ. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. *J Hepatol* 2017; **66**: 19-27 [PMID: 27545496 DOI: 10.1016/j.jhep.2016.08.004]

162 **Fattovich G**, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, Almasio P, Solinas A, Brouwer JT, Thomas H, Realdi G, Corrocher R, Schalm SW. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). *J Hepatol* 1997; **27**: 201-205 [PMID: 9252096 DOI: 10.1016/s0168-8278(97)80302-9]

163 **Iacobellis A**, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, Accadia L, Bombardieri G, Andriulli A. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. *J Hepatol* 2007; **46**: 206-212 [PMID: 17125876 DOI: 10.1016/j.jhep.2006.08.020]

164 **van der Meer AJ**, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández-Rodríguez CM, Aleman S, Ganne-Carrié N, D'Ambrosio R, Pol S, Trapero-Marugan M, Maan R, Moreno-Otero R, Mallet V, Hultcrantz R, Weiland O, Rutter K, Di Marco V, Alonso S, Bruno S, Colombo M, de Knegt RJ, Veldt BJ, Hansen BE, Janssen HLA. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. *J Hepatol* 2017; **66**: 485-493 [PMID: 27780714 DOI: 10.1016/j.jhep.2016.10.017]

165 **Carrat F**, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, De Ledinghen V, Larrey D, Haour G, Bronowicki JP, Zoulim F, Asselah T, Marcellin P, Thabut D, Leroy V, Tran A, Habersetzer F, Samuel D, Guyader D, Chazouilleres O, Mathurin P, Metivier S, Alric L, Riachi G, Gournay J, Abergel A, Cales P, Ganne N, Loustaud-Ratti V, D'Alteroche L, Causse X, Geist C, Minello A, Rosa I, Gelu-Simeon M, Portal I, Raffi F, Bourliere M, Pol S; French ANRS CO22 Hepather cohort. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. *Lancet* 2019; **393**: 1453-1464 [PMID: 30765123 DOI: 10.1016/S0140-6736(18)32111-1]

166 **Backus LI**, Belperio PS, Shahoumian TA, Mole LA. Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease. *Hepatology* 2019; **69**: 487-497 [PMID: 28749564 DOI: 10.1002/hep.29408]

167 **Kozbial K**, Moser S, Al-Zoairy R, Schwarzer R, Datz C, Stauber R, Laferl H, Strasser M, Beinhardt S, Stättermayer AF, Gschwantler M, Zoller H, Maieron A, Graziadei I, Trauner M, Steindl-Munda P, Hofer H, Ferenci P. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment. *Liver Int* 2018; **38**: 1028-1035 [PMID: 29136329 DOI: 10.1111/liv.13629]

168 **Butt AA**, Yan P, Simon TG, Abou-Samra AB. Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES. *Clin Infect Dis* 2017; **65**: 1006-1011 [PMID: 28903508 DOI: 10.1093/cid/cix364]

169 **Backus LI**, Belperio PS, Shahoumian TA, Mole LA. Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease. *Hepatology* 2018; **68**: 827-838 [PMID: 29377196 DOI: 10.1002/hep.29811]

170 **Fernández Carrillo C**, Lens S, Llop E, Pascasio JM, Crespo J, Arenas J, Fernández I, Baliellas C, Carrión JA, de la Mata M, Buti M, Castells L, Albillos A, Romero M, Turnes J, Pons C, Moreno-Planas JM, Moreno-Palomares JJ, Fernández-Rodriguez C, García-Samaniego J, Prieto M, Fernández Bermejo M, Salmerón J, Badia E, Salcedo M, Herrero JI, Granados R, Blé M, Mariño Z, Calleja JL. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. *Hepatology* 2017; **65**: 1810-1822 [PMID: 28170112 DOI: 10.1002/hep.29097]

171 **Vergniol J**, Foucher J, Terrebonne E, Bernard PH, le Bail B, Merrouche W, Couzigou P, de Ledinghen V. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. *Gastroenterology* 2011; **140**: 1970-1979, 1979.e1-1979.e3 [PMID: 21376047 DOI: 10.1053/j.gastro.2011.02.058]

172 **Cepeda JA**, Thomas DL, Astemborski J, Sulkowski MS, Kirk GD, Mehta SH. Increased Mortality Among Persons With Chronic Hepatitis C With Moderate or Severe Liver Disease: A Cohort Study. *Clin Infect Dis* 2017; **65**: 235-243 [PMID: 28329108 DOI: 10.1093/cid/cix207]

173 **Salerno F**, Borroni G, Moser P, Sangiovanni A, Almasio P, Budillon G, Capuano G, Muraca M, Marchesini G, Bernardi M, Marenco G, Molino G, Rossaro L, Solinas A, Ascione A. Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation. A prospective multicenter Italian study. AISF Group for the Study of Liver Transplantation. Associazione Italiana per lo Studio del Fegato. *J Hepatol* 1996; **25**: 474-480 [PMID: 8912146 DOI: 10.1016/s0168-8278(96)80206-6]

174 **Merkel C**, Gatta A, Zoli M, Bolognesi M, Angeli P, Iervese T, Marchesini G, Ruol A. Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. Comparison with the Pugh score. *Dig Dis Sci* 1991; **36**: 1197-1203 [PMID: 1893804 DOI: 10.1007/BF01307508]

175 **Albers I**, Hartmann H, Bircher J, Creutzfeldt W. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. *Scand J Gastroenterol* 1989; **24**: 269-276 [PMID: 2734585 DOI: 10.3109/00365528909093045]

176 **Addario L**, Scaglione G, Tritto G, Di Costanzo GG, De Luca M, Lampasi F, Galeota Lanza A, Picciotto FP, Tartaglione MT, Utech W, Macr M, Giannelli E, Ascione A. Prognostic value of quantitative liver function tests in viral cirrhosis: a prospective study. *Eur J Gastroenterol Hepatol* 2006; **18**: 713-720 [PMID: 16772827 DOI: 10.1097/01.meg.0000219104.40435.43]

177 **Ohnishi M**, Higuchi A, Matsumura H, Arakawa Y, Nakamura H, Nirei K, Yamamoto T, Yamagami H, Ogawa M, Gotoda T, Matsuoka S, Nakajima N, Sugitani M, Moriyama M, Murayama H. Involvement of Ornithine Carbamoyltransferase in the Progression of Chronic Hepatitis C and Liver Cirrhosis. *Int J Med Sci* 2017; **14**: 629-638 [PMID: 28824294 DOI: 10.7150/ijms.17641]

178 **Maier KP**, Talke H, Gerok W. Activities of urea-cycle enzymes in chronic liver disease. *Klin Wochenschr* 1979; **57**: 661-665 [PMID: 225605 DOI: 10.1007/bf01477666]

179 **El-Sheikh RM**, Mansy SS, Nessim IG, Hosni HN, El Hindawi A, Hassanein MH, AbdelFattah AS. Carbamoyl phosphate synthetase 1 (CPS1) as a prognostic marker in chronic hepatitis C infection. *APMIS* 2019; **127**: 93-105 [PMID: 30698308 DOI: 10.1111/apm.12917]

180 **Byrnes V**, Miller A, Lowry D, Hill E, Weinstein C, Alsop D, Lenkinski R, Afdhal NH. Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. *J Hepatol* 2012; **56**: 549-556 [PMID: 22027578 DOI: 10.1016/j.jhep.2011.09.015]

181 **Alsop D,** Younossi Z, Stepanova M, Afdhal NH. Cerebral MR spectroscopy and patient-reported mental health outcomes in hepatitis C genotype 1 naive patients treated with ledipasvir and sofosbuvir. *Hepatology* 2014; **60**: 221a-221a

182 **Curry MP,** Moczynski NP, Liu L, Stamm L, Yun C, Brainard DM, McHutchison JG, Alsop D, Afdhal NH. The Effect of Sustained Virologic Response on Cerebral Metabolism and Neurocognition in Patients with Chronic Genotype 1 Hcv Infection. *J Hepatol* 2016; **64**: S797-S797

183 **Dusheiko G**. The impact of antiviral therapy for hepatitis C on the quality of life: a perspective. *Liver Int* 2017; **37 Suppl 1**: 7-12 [PMID: 28052638 DOI: 10.1111/liv.13292]

184 **Puente Á**, Cabezas J, López Arias MJ, Fortea JI, Arias MT, Estébanez Á, Casafont F, Fábrega E, Crespo J. Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy. *Rev Esp Enferm Dig* 2017; **109**: 17-25 [PMID: 27990835 DOI: 10.17235/reed.2016.4235/2016]

185 **Afdhal N,** Everson GT, Calleja JL, McCaughan G, Bosch J, Denning J, Brainard DM, McHutchison JG, Brandt-Sarif T, An D, Charlton M, Reddy KR, Asselah T, Gane E, Forns X. Effect of long term viral suppression with sofosbuvir plus ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension. *J Hepatol* 2015; **62**: S269-S270 [DOI: 10.1016/S0168-8278(15)30167-7]

186 **Mandorfer M**, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, Stern R, Chromy D, Stättermayer AF, Reiberger T, Beinhardt S, Sieghart W, Trauner M, Hofer H, Ferlitsch A, Ferenci P, Peck-Radosavljevic M. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. *J Hepatol* 2016; **65**: 692-699 [PMID: 27242316 DOI: 10.1016/j.jhep.2016.05.027]

187 **Mauro E**, Crespo G, Montironi C, Londoño MC, Hernández-Gea V, Ruiz P, Sastre L, Lombardo J, Mariño Z, Díaz A, Colmenero J, Rimola A, Garcia-Pagán JC, Brunet M, Forns X, Navasa M. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. *Hepatology* 2018; **67**: 1683-1694 [PMID: 28960366 DOI: 10.1002/hep.29557]

188 **Mandorfer M**, Kozbial K, Schwabl P, Chromy D, Semmler G, Stättermayer AF, Pinter M, Hernández-Gea V, Fritzer-Szekeres M, Steindl-Munda P, Trauner M, Peck-Radosavljevic M, García-Pagán JC, Ferenci P, Reiberger T. Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. *Hepatology* 2020; **71**: 1023-1036 [PMID: 31365764 DOI: 10.1002/hep.30885]

189 **Fattovich G**, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterology* 2004; **127**: S35-S50 [PMID: 15508101 DOI: 10.1053/j.gastro.2004.09.014]

190 **Ganne-Carrié N**, Chastang C, Chapel F, Munz C, Pateron D, Sibony M, Dény P, Trinchet JC, Callard P, Guettier C, Beaugrand M. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. *Hepatology* 1996; **23**: 1112-1118 [PMID: 8621142 DOI: 10.1002/hep.510230527]

191 **Reig M**, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, Díaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X, Bruix J. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. *J Hepatol* 2016; **65**: 719-726 [PMID: 27084592 DOI: 10.1016/j.jhep.2016.04.008]

192 **Conti F**, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti S. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. *J Hepatol* 2016; **65**: 727-733 [PMID: 27349488 DOI: 10.1016/j.jhep.2016.06.015]

193 **Kozbial K**, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Stauber R, Stättermayer AF, Beinhardt S, Graziadei I, Freissmuth C, Maieron A, Gschwantler M, Strasser M, Peck-Radosalvjevic M, Trauner M, Hofer H, Ferenci P. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. *J Hepatol* 2016; **65**: 856-858 [PMID: 27318327 DOI: 10.1016/j.jhep.2016.06.009]

194 **Cheung MCM**, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, Brown A, Gelson WTH, MacDonald DC, Agarwal K, Foster GR, Irving WL; HCV Research UK. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. *J Hepatol* 2016; **65**: 741-747 [PMID: 27388925 DOI: 10.1016/j.jhep.2016.06.019]

195 **ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts)**. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. *J Hepatol* 2016; **65**: 734-740 [PMID: 27288051 DOI: 10.1016/j.jhep.2016.05.045]

196 **D'Ambrosio R**, Colombo M. Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression? *Liver Int* 2016; **36**: 783-790 [PMID: 26936383 DOI: 10.1111/liv.13106]

197 **Ioannou GN**, Beste LA, Green PK, Singal AG, Tapper EB, Waljee AK, Sterling RK, Feld JJ, Kaplan DE, Taddei TH, Berry K. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. *Gastroenterology* 2019; **157**: 1264-1278.e4 [PMID: 31356807 DOI: 10.1053/j.gastro.2019.07.033]

**Footnotes**

**Conflict-of-interest statement:** George J is supported by the Robert W Storr Bequest to the Sydney Medical Foundation, University of Sydney; a National Health and Medical Research Council of Australia (NHMRC) Program Grant, No. APP1053206 and APP1149976) and Project grants, No. APP1107178 and APP1108422 and is on the advisory boards of Gilead, AbbVie, Novo Nordisk, MSD, Intercept, and Janssen; Grønbæk H received grants from the NOVO Nordisk Foundation, ‘‘Savværksejer Jeppe Juhl og hustru Ovita Juhls mindelegat”, AbbVie, and Intercept and is on the advisory board of Ipsen and Novartis; Laursen TL, Sandahl TD, and Kazankov K have no conflicts of interest to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** January 31, 2020

**First decision:** February 24, 2020

**Article in press:** May 30, 2020

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Denmark

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P- Reviewer:** El-Shabraw MHF, Yang SS **S- Editor:** Wang JL **L- Editor:** A **E- Editor:** Liu MY

**Figure Legends**



**Figure 1 Release of viral particles, viral proteins, and RNA from hepatocytes in hepatitis C infection, and subsequent shedding of soluble CD163 and soluble mannose receptor from the surface of macrophages in response to exogenous and endogenous stimuli.** PAMP: Pathogen-associated molecular pattern; DAMP: Damage-associated molecular pattern; MR: Mannose receptor; sMR: Soluble mannose receptor; sCD163: Soluble CD163.



**Figure 2 Proposed time-line for liver-related effects of direct-acting antiviral therapy.** DAA: Direct-acting antiviral; EOT: End of treatment; SVR12: Sustained virologic response at 12 wk post-treatment; SVR52: Sustained virologic response 1 year after treatment.